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ABSTRACT
REGULATION OF CRBP1 IN MAMMARY EPITHELIAL CELLS
SEPTEMBER 2010
STACY L. PEASE, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sallie Smith Schneider

Breast cancer is the second leading cause of death of women in the United States,
warranting further investigation into preventative therapies. It has been well
documented that early pregnancy results in a lifetime decreased risk of breast
cancer in humans and mounting evidence suggests that the retinoic acid pathway
may play an important role in this protective effect. Cellular retinol binding
protein‐1 (CRBP1) is an essential component of the retinoic acid pathway and we
propose that it plays an important role in pregnancy‐induced protection against
breast cancer. In order to investigate the role of CRBP1 in parity‐induced
protection against breast cancer, we utilized both mouse and human mammary
epithelial cells. We examined the effect that pregnancy has on CRBP1 expression,
how CRBP1 is regulated by growth promoting and inhibiting agents, if loss of CRBP1
is essential for the induction of the apoptotic pathway, and how CpG methylation of
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key breast cancer genes relates to known risk factors for the disease. Based on our
study, CRBP1 is persistently upregulated in response to pregnancy in the mouse
mammary gland at both the RNA and protein levels. Using a cell culture model, we
established that CRBP1 is regulated by chemical agents that both promote and
inhibit cellular growth. Utilizing CRBP1 knockout mice, we demonstrated that
CRBP1 is not essential for induction of radiation induced apoptosis in parous mice.
Finally, through methylation analysis, we examined how known breast cancer risk
factors correlate to CpG methylation of three important genes for breast cancer and
noted interesting trends that warrant future study.
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CHAPTER 1
OVERALL INTRODUCTION
Breast cancer is the second leading cause of cancer related death in women in the
United States, resulting in an excess of 40,000 deaths in 2008 (Ries et al. 2008).
Although advances in breast cancer therapies have improved life expectancy for nonmetastatic breast cancer, cure rates for metastasized breast cancer remain low. In light of
this, it is imperative that the development of preventative therapies against breast cancer
be a research focus. One approach to breast cancer prevention is through a better
understanding of parity-induced protection. It has been well documented that women
who have a full term pregnancy before the age of twenty-four have a decreased lifetime
risk of developing breast cancer and that additional pregnancies increase this protection
(Russo et al. 2005). This protective effect has also been observed in rodents. It has been
shown that pregnancy results in mammary gland differentiation, as well as persistent
changes to gene expression (Verlinden et al. 2005). Despite these observations, the
molecular mechanisms responsible for this effect are largely unknown.
Mounting evidence suggests that the retinoic acid pathway may be important in
parity-induced protection against breast cancer. The retinoic acid pathway is responsible
for converting exogenous Vitamin A into retinoic acid that the body can store and later
utilize. It has been shown that retinoids are important for the regulation of cell
proliferation, mammary gland differentiation, and apoptosis and that components of this
pathway are upregulated in response to early pregnancy (Verlinden et al. 2005). Loss of
retinoic acid signaling has been implicated in breast cancer development and retinoic acid
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signaling has been proven necessary for proper mammary gland morphogenesis (Wang et
al. 2005). Clinically, all-trans retinoic acid (ATRA) has been used as a
chemotherapeutic and chemopreventative agent in the treatment of several cancers.
Collectively, this evidence suggests that regulation of the retinoic acid pathway is
important in the prevention of breast cancer.
Cellular retinol-binding protein I (CRBP1) is an essential component of the
retinoic acid pathway (Ghyselinck et al. 1999). CRBP1 is an intracellular carrier protein
that is responsible for transporting retinol for storage in the cell. Several significant
findings indicate that CRBP1 is an important gene in breast cancer. CRBP1 expression
is down regulated in 24% of human breast cancers (Kuppumbatti et al. 2000) and CRBP1
silencing through promoter methylation is a common epigenetic event in the progression
of breast cancer (Esteller et al. 2002). Additionally, CRBP1 warrants further
investigation due to a number of studies indicating its role in regulating cell
differentiation, anchorage-independent growth, and tumor suppression (Farias et al.
2005). A microarray study examining transcriptional changes within the mammary gland
in response to estrogen and progesterone levels mimicking pregnancy identified CRBP-1
to be upregulated (Lu et al. 2008). All of this evidence points to the important role of
CRBP-1 in breast cancer and supports our investigation into its role in mammary
epithelial cells.
We propose that changes to CRBP1 expression play an important role in breast
cancer development and that understanding the role of CRBP1 may be vital to developing
preventative therapies. Utilizing mouse models, we will examine how pregnancy affects
CRBP1 expression and how loss of CRBP1 impacts cell proliferation and apoptosis in the
2

mammary gland. In vitro studies using immortalized human mammary epithelial cells
treated with various growth enhancing and growth inhibitory reagents will provide an
examination of CRBP1 expression patterns in breast tissue.

Finally, methylation

analysis of human mammary epithelial cells donated by patients at a local hospital will
provide evidence about how age and parity impact promoter hypermethylation of several
genes, including CRBP1.
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CHAPTER 2
CRBP1 IS PERSISTENTLY UPREGULATED IN RESPONSE TO
PREGNANCY

Introduction
The correlation between early pregnancy and decreased risk of developing breast
cancer is well documented in humans and is reproducible in animal models. Although
the molecular mechanisms responsible for this effect are unascertained, it has been shown
that pregnancy hormone levels of estrogen and progesterone result in the sensitization of
the tumor suppressor gene, p53, to DNA damage in rodents (Sivaraman et al. 2001,
Minter et al. 2002). It has also been documented that human mammary epithelial cell
treatment with retinoids results in the upregulation of p53 in vitro (Zhang et al. 2005).
Furthermore, retinoids have been shown to have potent chemopreventive abilities against
breast tumorigenesis in rodents (Wu et al. 2000). Taken together, these observations
about p53 suggest a potential relationship between parity-induced protection and the
retinoic acid pathway.
As a DNA damage detection gene, p53 plays an important role in DNA damage
repair and is capable of inducing the apoptosis cascade. Breast cancer develops from an
accumulation of mutations and DNA damage that eventually lead to a loss of cell cycle
control. Given the important role that p53 plays in DNA damage repair and programmed
cell death, it is clear that p53 is a vital tumor suppression gene. We propose that
identifying other genes that are transcriptionally upregulated in response to pregnancy
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and are involved in p53 signaling pathways could provide important insight into the
parity-induced protection mechanism.
In an effort to further characterize the molecular effects of pregnancy, researchers
have developed the means to artificially replicate the effects of pregnancy through the
administration of hormones. Doses of estrogen and progesterone that produce circulating
levels of hormones equivalent to those found in mid-pregnancy replicate the effects of
pregnancy with regard to protection against carcinogen-induced breast cancer in cell
culture and rodent models (Guzman et al. 1999). Utilizing this method, a microarray
study was conducted in D. Joseph Jerry’s laboratory to show transcriptional gene changes
in response to pregnancy-level estrogen and progesterone administration. The results of
the microarray identified CRBP1 as a gene that is upregulated in response to estrogen and
progesterone exposure (Lu et al. 2008). Based on this finding, it is known that CRBP1
transcription can be stimulated by pregnancy hormones in vitro, but this effect has yet to
be confirmed in vivo.
We propose that CRBP1 expression will be persistently changed in response to
pregnancy in vivo. Through the use of a mouse pregnancy study, we will examine
CRBP1 expression through PCR analysis and also CRBP1 translational changes using
immunohistochemistry. This experiment will prove that the effect of pregnancy
hormones on CRBP1 expression in vitro can be replicated in a mouse model in vivo and
will further our evidence that CRBP1 plays an important role in pregnancy-induced
protection against breast cancer.
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Materials and Methods
Animal Husbandry & Surgery
12- 8-week-old female nulliparous BALB-c mice were allowed to become
pregnant or not. Mice underwent a gestation period of three weeks, birthed their pups,
pups nursed for three weeks and were then weaned. The mammary glands of the female
mice were allowed to involute for two weeks. Mice were then euthanized at 16 weeks of
age using carbon dioxide inhalation. The 4th inguinal mammary glands were removed
from the left side and paraffin-embedded for immunohistological staining. The 4th
inguinal mammary glands from the right side were flash frozen using liquid nitrogen for
RNA isolation (Fig 2.1).
RNA Isolation
Mouse mammary glands harvested for RNA isolation were weighed and averaged
between 50-80 mg. 1 mL of TRIZOL (Invitrogen) reagent was added to each gland
and the tissue was homogenized. Samples were centrifuged at 12 X g for 15 minutes,
supernatant was removed, and fat was discarded. 0.2 mL of chloroform was added to
each sample, samples were incubated at room temperature for 3 minutes, and then
centrifuged at 4°C at 12 x g for 15 minutes. Following centrifugation, the aqueous phase
was removed and the RNA was precipitated using 0.5 mL of isopropyl alcohol. After a
brief incubation period, samples were centrifuged again at 4°C. After centrifugation, the
supernatant was removed from the samples and the RNA pellet was washed using 1 mL
of 75% ethanol. Samples were again centrifuged at 4°C at 7500 x g for 5 minutes. The
RNA pellet was briefly dried and the RNA was resuspended in RNase free water. RNA
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quality was ensured by spectroscopy and samples were diluted to 100ng/µl and stored at 20°C for future use.
Quantitative PCR
PCR reactions to measure CRBP1 expression in mouse DNA isolated from the
experiment were conducted using an Mx4000 Multiplex Quantitative PCR system
(Stratagene). CRBP1 primers utilized were F 51 AGTGGATGGTGGAAGAAAC 31 and
R 51 CCCAGGCCTGTGTAAGGTA 31 and GAPDH was used as a control for the
experiment with primers F 51 TTCACCACCATCGAGAAGGC 31 and
R 51 GGCATGGACTGTGGTCATGA 31. 1 µL of DNA was amplified in a 10 µL
reaction mixture containing 2.4 µL of Mastermix (Brilliant® SYBR® Green QPCR
Mater Mix, Stratagene), 2.4 µL of DNase fee water, 0.6 µL each of 12.5nM primers, and
0.4 µL of RT. Each PCR product was amplified over 40 cycles at an annealing
temperature of 55°C. Included with each PCR were a series of controls.
Immunohistochemistry
All immunohistochemical studies were performed using the Dakocytomation
LSAB System-HRP kit (Dako, Denmark). Formalin-fixed, paraffin embedded
mammary tissue was cut on a Leica microtome at a thickness of 4µm on Superfrost plus
slides. Slides were dried by microwave for 1 minute and then in a 62°F oven for 15
minutes. Slides were then deparaffinized three times with xylene, cleared with graded
ETOH (100% X2, 95%, 70%), and rinsed in DIH20. The EZ-Retriever system
(BioGenex, San Ramon CA) for antigen retrieval was used with Antigen Retrieval Citra
Solution 10X (BioGenex, San Ramon CA)(citrate buffer pH 6.0) and was brought to a
7

working 1X dilution with DIH2O. Slides were allowed to cool for 20 minutes then rinsed
in DIH2O and placed in TBS buffer with Polysorbate 20 (2.5 mL to 5 liters of TBS).
Slides were then loaded on the DakoCytomation Autostainer (Dako, Denmark) and
stained according to the manufacturer description. The primary antibody used was a
polyclonal antibody to CRBP or Actin with a secondary anti-rabbit antibody (Dako
polymer detection kit). Sections were then stained with diaminobenzidine (DAB)
chromogen for 7 minutes. The slides were then counterstained for 15 seconds in Mayer’s
hematoxylin, then washed in glacial acetic acid water for 15 seconds, and washed in
ammonia water to blue. Finally, slides were dehydrated in ETOH and xylene before
manual coverslipping.
Results
In this experiment, we proposed to examine persistent changes in CRBP1 gene
expression as a result of pregnancy. RNA was isolated from parous and nulliparous
mouse mammary glands and quantitative PCR was used to examine changes in CRBP1
transcription levels. Upon comparison of the two experimental groups, we found that
CRBP1 expression was significantly upregulated in the parous mice (Fig 2.2). The
parous mouse mammary glands showed a significant increase in CRBP1 transcription of
approximately 4 times the relative fold induction of the nulliparous mice. The
nulliparous mouse RNA showed no significant change in CRBP1 expression. This result
confirmed that CRBP1 expression was upregulated at the transcriptional level in response
to pregnancy in vivo.
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After discovering the transcriptional increase in CRBP1, we wanted to examine
changes to gene expression at the protein level. Using the parous and nulliparous mouse
mammary glands that were paraffin-embedded, we utilized an antibody for CRBP to
examine expression and distribution of the CRBP protein. The parous mouse mammary
glands showed a significant amount of CRBP staining in the myoepithelial and the
luminal epithelial cells while the nulliparous glands only expressed CRBP in the
myoepithelial cells (Fig 2.3). Of note, was the unexpected observation that CRBP was
found in the nucleus as well as the cytoplasm. Immunohistochemical staining of
mammary glands from CRBP1 knock out animals confirmed that our antibodies were
specific for CRBP1. This assay confirmed that CRBP1 was persistently upregulated in
the parous mouse mammary gland even after two weeks of involution.
Discussion
The molecular mechanisms responsible for parity-induced protection are still
under investigation. Based on a key microarray study mimicking the effects of
pregnancy that showed CRBP1 upregulation in response to increased levels of estrogen
and progesterone, we proposed that CRBP1 may play an important role in parity-induced
protection and should be altered in response to pregnancy. In this study, we confirmed
that CRBP1 transcription is persistently upregulated in response to pregnancy in vivo and
that CRBP1 translational changes are also observed.
One of the most significant findings of this experiment was the persistent
upregulation of CRBP1 transcription after mammary gland involution. Postlactational
involution is an important remodeling process the breast undergoes after lactation

9

involving cell death via apoptosis. There is a growing body of literature suggesting that
pregnancy and the breast remodeling that occurs during involution plays a significant role
in reducing long-term breast cancer risk (Radisky et al, 2009). Interestingly, p53 mediates
the apoptosis observed during involution and becomes primed to respond to future
carcinogenic challenges after pregnancy (Jerry et al, 1999). The observation that CRBP1
continues to be upregulated even two weeks after weaning suggests that pregnancy relays
a permanent effect on its expression in the mammary gland, similar to published findings
about p53. This finding adds support to our hypothesis that CRBP1 plays an important
role in parity-induced protection and further suggests a potential relationship between
CRBP1 and p53.
The other significant finding of this experiment was the localization change of
CRBP1 protein expression in the mammary gland cells. Even with an observed
transcriptional change, not all genes are also impacted at the protein level, so we were
intrigued when the immunohistochemical analysis showed new expression of CRBP1 in
the parous mammary gland. As was observed in the nulliparous mice, prior to pregnancy
CRBP1 is localized in the myoepithelial cells and is not found in the epithelial or
cytoplasm. After pregnancy and involution, CRBP1 expression was located in the
epithelial cells and cytoplasm. This new localization of CRBP1 is an important
observation and warrants further investigation in the future.
One challenge we initially experienced with this experiment was demonstrating
the specificity of our CRBP antibody. CRBP exists in several forms in the body, CRBP1
being just one of them. After immunohistochemistry, we observed that CRBP expression
in the parous mice was found in the epithelium and cytoplasm, in contrast to the
10

myoepithelial CRBP expression in the nulliparous mice, but we were unable at that time
to prove that is was specifically CRBP1 expression we were visualizing. In order to
prove the specificity of our antibody, we later utilized CRBP1-null mice and repeated the
experiment. We were able to demonstrate that our antibody was specific for CRBP1,
strengthening the significance of this experiment.
This experiment provided important information about the impact of pregnancy
on CRBP1 expression. We were able to confirm that CRBP1 expression, both at the
transcription and translation levels, is permanently altered in response to pregnancy in
vivo. Based on this experiment, we can say that CRBP1 expression is temporally
expressed at the correct time to play an important role in parity-induced protection
against breast cancer and propose to continue characterizing the role of this gene.
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Figure 2.1 Experiment Overview
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Figure 2.2 qPCR gene expression results for CRBP1
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Figure 2.3 Immunohistochemical staining of mouse mammary glands for CRBP1

Nulliparous Mammary Gland

Parous Mammary Gland
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CHAPTER 3
LOSS OF CRBP1 DOES NOT EFFECT CELLULAR APOPTOSIS IN RESPONSE TO
RADIATION INDUCED DNA DAMAGE

Introduction
As was demonstrated in the previous experiment, CRBP1 expression is
persistently upregulated in response to pregnancy in the mouse mammary gland.
Although these results indicate a change to CRBP1 expression in response to parity, they
do not explain if this change contributes to the phenomenon of parity-induced protection
and, if it does, by what mechanism. In this experiment, we propose to further investigate
how CRBP1 may be contributing to parity-induced protection against breast cancer,
specifically by upregulating the expression or sensitization of p53.
P53 is a DNA damage repair gene and an important tumor suppressor. P53 is a
known activator of programmed cell death, or apoptosis, both during development and in
response to irreparable DNA damage. Loss of p53 expression has been shown to be an
essential part of tumorigenesis and restoration of the gene leads to tumor regression in
vivo (Ventura et al. 2007). Thus, loss of p53 expression, which is common in many types
of cancer, prevents the apoptotic cascade from being properly activated and allows cells
with DNA damage cells to replicate.
Treatment of 76N tert human mammary epithelial cells with retinoids has been
shown to increase the expression p53 in vitro (Zhang et al. 2005). It has also been
established that p53 is sensitized to DNA damage during pregnancy (Lu, et al. 2008, Tu,
et al. 2005, Sivaraman et al. 2001). When comparing p53 and CRBP1 regulation they
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both have been shown to be positively regulated in response to pregnancy or hormonal
treatments mimicking pregnancy. P53 is a downstream target of the retinoic pathway of
which CRBP1 is a member. Based on this data, it is possible that there is a relationship
between CRBP1 upregulation and persistent expression in response to pregnancy and the
sensitization of p53 to DNA damage during pregnancy. We hypothesize that CRBP1
expression is vital to p53 sensitization in response to pregnancy and that loss of CRBP1
expression will result in p53 have a decreased apoptotic response to radiation-induced
DNA damage.
One useful technique to investigate the relationship between two genes is to
eliminate the expression of the upstream gene and to see how this loss affects its
downstream gene target. In order to accomplish this in our experiment, we chose to
utilize transgenic mice created in the lab of Pierre Chambon lacking CRBP1 (Quadro et
al. 1999). Utilizing the CRBP1 knock-out mice and wild type mice of the same
background, we propose to examine if the loss of CRBP1 has an effect on p53 and its
DNA damage response in the cell.
One mechanism for cellular death is apoptosis or programmed cell death. When a
cell’s DNA is damaged beyond repair, the apoptotic cascade, which includes endogenous
endonucleases, is activated to dispose of it. The endonuclease is responsible for cleaving
the DNA into oligonucleosomes generating free 3’-OH groups at the end of each
fragment. A TUNEL assay labels the free hydroxyl groups with fluorescein-conjugated
deoxynucleotides. When excited, the fluorescein generates a fluorescent signal that can
be detected using fluorescence microscopy. Cells that are fluorescent are then counted as
TUNEL-positive and undergoing apoptosis. In this experiment, we plan to use a TUNEL
16

assay to measure the percentage differences of TUNEL-positive cells between CRBP1
null and wild-type mice and extrapolate that finding to an understanding of the
relationship between CRBP1 and p53.
CRBP1 expression is often lost during the progression of breast cancer. In vitro
studies have suggested the CRBP1 is involved in cellular differentiation and that it may
play a role in ductal epithelial cells susceptibility to cell death (Farias et al. 2005,
Kuppumbatti et al. 2001). Thus the loss of expression may impact the ability of the
mammary gland to remove unwanted cells and increase risk of breast cancer. We would
like to see if the loss of CRBP1 expression affects the expression or activity of the tumor
suppressor p53 and whether there is a reduction in cellular death as a result.
Materials and Methods
Animal Husbandry
CRBP1 knockout C57 BL/6.129 mice were created in the laboratory of Pierre
Chambon (University of Strassbourg) and were provided to us by William Blaner
(Columbia University). Mice wild-type for CRBP1 were also obtained with a
C57 BL/6.129 background. Mice were backcrossed three times to BALB/c mice to
ensure a susceptible background to breast cancer. Mouse genotypes were confirmed
throughout the experiment to ensure that the knockout mice truly lacked CRBP1.
Experimental Procedures and Surgery
As is shown in Figure 3.1, 6-week old BALB/c-C57 BL6.129 mice were divided
into four experimental groups with 9 mice per group: wild-type nulliparous, wild-type
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parous, CRBP1 knockout nulliparous, and CRBP1 knockout parous. Mice were then
impregnated or not. After a full cycle of pregnancy, 1 week of lactation, and three weeks
of involution, mice were treated 5Gy of whole body radiation and then put back into their
cages for 6 hours to allow DNA damage and cellular death to occur. Mice were then
euthanized using carbon dioxide inhalation. The 4th inguinal mammary glands of the
mice were then removed and paraffin imbedded for immunohistochemical analysis and
TUNEL assay. Spleens from one mouse in each experimental group were also removed
to confirm that the whole-body radiation was successful in inducing DNA damage.
TUNEL Assay
For our TUNEL assay, we used the Calbiochem® Fluorescein-FragEL (Fragment
End Labeling)™ DNA Fragmentation Detection Kit. Kit procedures for conducting the
assay were followed. Completed slides were labeled with the genotype and parity status
of the mouse as well as their number. Slides were stored at 20°C when not been
examined or photographed.
Fluorescent Microscopy and Cell Counting
After completing the TUNEL assay, slides were examined for apoptotic cells
using a Nikon Eclipse TE2000-U™ and Nikon X-Cite Series 120™ microscope system
for fluorescence and Metavue™ to view and manipulate the images. Each animal was
represented by one slide. For each slide, 5 mammary ducts were randomly chosen using
DAPI only. After selecting a duct, a picture was taken with DAPI alone, TUNEL alone,
and then the two images were overlaid to reveal positive TUNEL staining (Figure 3.2).
Positive epithelial TUNEL cells were then counted for each duct as well as the total
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number of epithelial cells. Statistical analysis was then conducted using Microsoft Excel
to determine the percentage of TUNEL-positive cells in each of the experimental groups
(Figure 3.3).
Results
CRBP1 is not required for parity-induced p53 sensitization to DNA damage and
activation of the apoptotic cascade (Figure 3.4). Utilizing CRBP1 knock-out mice and
wild-type mice of the same background, we conducted a pregnancy study, inducing a
DNA damage response, and conducted a TUNEL assay to examine changes in apoptotic
death. Upon examination of the TUNEL-positive percentages for each experimental
group, there was no significant difference between the CRBP1 null parous mice and the
CRBP1 wild-type mice. This finding suggests that CRBP1 does not play an essential role
in p53’s ability to respond to DNA damage and induce apoptosis.
Discussion
This study definitively demonstrated that CRBP1 expression is not required for
p53 sensitization during pregnancy and its response to radiation-induced DNA damage.
The results of our experiment showed that there was no statistical difference in the
amount of apoptosis between the wild-type parous mice and those with those lacking
CRBP1. Although our hypothesis that CRBP1 played an important role in priming p53
as part of its role in parity-induced protection against breast cancer was not confirmed in
this experiment, we were able to rule out one of the ways that CRBP1 could contribute to
tumor suppression.
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There were two major successes of this experiment: backcrossing the wild-type
and knockout mice and accomplishing the TUNEL assay using the mouse tissue. One of
the initial challenges we encountered in this experiment was back-crossing the knock-out
and wild type mice C57 BL/6.129 mice onto a BALB/c background. This was an
important step in our experimental design as the BALB/C background is more susceptible
to mammary carcinogenesis. We backcrossed the mice three times before beginning our
experiment. Initially, the knockout mice had challenges breeding and, when they did,
had low litter counts. Eventually, once they had been successfully backcrossed twice, the
breeding issues resolved themselves, but it did slow the experiment. It was also
important that we confirm that the backcrossed null animals were in fact lacking CRBP1.
Using PCR analysis, we did confirm prior to setting up the experimental groups that all of
the animals were in fact CRBP1 null or CRBP1 wild-type and later further confirmed this
at the protein level using immunohistochemistry (Figure 3.4). Additionally, because we
had fewer knockout breeding pairs than wild-types, we had to conduct the experiment in
two waves, with 4 mice in each group the first, and 5 in the second. Although the
experimental procedures for the two sets were identical, it would have been preferable to
have had all of the animals in one set in order to ensure that no environmental factors
affected them.
The other major success of this experiment was getting the TUNEL assay to work
with the mouse mammary gland tissue. Although this assay was conducted using a kit
(Calbiochem Frag-El), TUNEL assays can be challenging with certain tissues. We were
able to observe apoptotic cells in every experimental group and confirm that the assay did
work properly. Our death counts were higher in the parous mice versus nulliparous mice
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which is in agreement with the literature, but our overall percentages of TUNEL-positive
cells in the parous animals were lower than the literature. We think this could be due to
the fact that we only completed 3 backcrosses on the susceptible mouse background and
that we probably should have done 6 backcrosses to be certain that the majority of the
genes were coming from the BALB/c strain.
A challenge we experienced in this study was examining p53 expression using
immunohistochemistry. Initially, we set out to conduct the TUNEL assay to compare the
amount of apoptotic activity between parous CRBP1 null and wild-type animals, but we
also planned to utilize a p53 specific-antibody to examine protein-level changes in gene
expression. Unfortunately, we were unable to complete this part of the experiment
because we were unable to obtain a working p53 antibody. This piece of data would
have been helpful in understanding the TUNEL assay results as we can only extrapolate
from the TUNEL results that CRBP1 loss did not affect p53 regulation, but it would have
been beneficial to have confirmed this using immunohistochemistry.
Based on the results of this experiment, CRBP1 is not required for p53-mediated
apoptosis in response to radiation-induced DNA damage. Although this finding may be
accurate, there two ways that this experiment could be improved upon in the future to
ensure that our finding is correct. Both CRBP1 and p53 are known to be regulated by
estrogen. In vivo, the female mouse is undergoing her own estrous cycle, but we did not
account for this in our experimental design. If this experiment is to be repeated, the
timing of the estrous cycle of the individual mice in the study should be better controlled
for utilizing regular blood tests. This would help to help to eliminate one possible source
of error. Additionally, one of the challenges we experienced in conducting the TUNEL
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analysis was uniformity within the mouse mammary ducts in terms of size. Since only
one slide was prepared per mouse, there were animals that only had very small or very
large ducts, which potentially could have impacted our statistical analysis. In the future,
at least two slides, preferably from different depths in the paraffin-imbedded gland or
from different glands should be utilized to control for such error.
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Figure 3.1 Experiment Overview
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Figure 3.2 Sample of TUNEL pictures

Top row is TUNEL (+) parous and nulliparous mice and bottom row is TUNEL (-)
parous and nulliparous mice. Positive cells are azure in color.
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Figure 3.3 Percent of TUNEL-positive cells for each experimental group
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Figure 3.4 Immunohistochemical staining for CRBP1 expression in CRBP1 knockout and
wild-type mice, parous and nulliparous
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Staining confirms that CRBP1 null mice do not express CRBP1 protein.
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CHAPTER 4
CRBP1 IS REGULATED BY AGENTS WHICH INHIBIT AND PROMOTE GROWTH

Introduction
The role of CRBP1 in pregnancy-induced protection against breast cancer is still
under investigation, but research has uncovered clues about the important role CRBP1
plays in the cell. Studies have demonstrated that retinoids are important for proper cell
growth and differentiation and that treatment of MCF-7 breast cancer cells in vitro with
retinoic acid can induce cell cycle arrest (Tighe and Talmage 2004, Zhu et al. 1997). In
addition to being a critical player in the retinoic acid pathway, CRBP1 has independently
been implicated in cell growth regulation and tumor suppression. Specifically, CRBP1
has been shown to play a role in anchorage-independent growth, cell differentiation, and
cell proliferation (Kuppumbatti et al. 2001, Farias et al. 2005). One of the key steps in
cancer progression is the loss of cell cycle regulation and, consequently, uncontrolled
growth. Retinoids have already been shown to have tumor suppressive activity through
growth regulation, and a better understanding of how CRBP1 is regulated in the cell may
strengthen our understanding of its role in controlling cellular growth and tumor
suppression.
There are many natural and synthetic chemical compounds that have been
previously shown to regulate growth in the cell. We propose that by treating
immortalized human mammary epithelial cells with chemical agents whose effects on
cell growth are known, we can determine if CRBP1 expression is altered in response their
activity. We hypothesize that if CRBP1 regulates cell proliferation in human mammary
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epithelial cells then compounds that are known to effect cell growth may regulate its
expression. In order to select appropriate treatments that would contribute to the overall
understanding of CRBP1 and cell regulation, we chose chemical agents that have been
previously shown to regulate CRBP1 as controls and agents whose effects on CRBP1 are
unknown, but have been shown to work through receptors and pathways CRBP1 is
known to interact with.
This experiment will allow us to examine if growth inhibitory agents regulate
CRBP-1. We would like to examine the expression of CRBP1 in immortal mammary
epithelial cells in response to 9-cis retinoic acid, TGFb, IGFBP3, and Tamoxifen. These
agents have all been shown to inhibit growth or act in a preventive fashion. As a known
downstream target of the retinoic acid pathway, we expect that CRBP-1 will be
upregulated in response to retinoic acid treatment in epithelial cells. In fibroblasts, it has
been shown that CRBP1 is regulated by TGFβ, transforming growth-factor beta, and it is
has also been shown that retinoids act, in part, by activating TGFβ (Xu et al. 2001,
Kojima et al. 1993). Based on these observations, we propose to test whether TGFβ
alone is sufficient to upregulate CRBP1 expression in human mammary epithelial cells.
IGFBP3, insulin-like growth factor binding protein 3, is a downstream gene target of
TGFβ and is also been shown to increase TGFβ signaling (Schedlich et al. 2002).
Furthermore, it inhibits IGF-1 induced signaling, a gene known to increase cell
proliferation. We would like to test the idea that IGFBP3 will increase CRBP1
expression. In the uterus, we have previously observed that CRBP-1 is upregulated in
response to Tamoxifen, a potent cancer drug often used in the treatment of estrogenreceptor positive breast cancer. However, the uterine cells can have very different
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responses to Tamoxifen than mammary epithelial cells. We would like to determine
whether Tamoxifen will increase CRBP1 expression in the mammary epithelial cells.
In contrast, we expect to see that CRBP-1 expression is abrogated by growth
inducing agents. IGF-1, insulin-like growth factor 1, is known to promote cellular
proliferation. We have previously noted that IGF-1 inhibits estrogen and progesterone
induced CRBP1 expression and plan to confirm this finding using the mammary
epithelial cells in culture. Insulin is known to activate the IGF receptor consequently
promoting cellular growth. In this experiment we would like to whether treating cells
with physiological levels of insulin alone is sufficient to block CRBP1 expression.
Materials and Methods
Cell Culture
76N tert, immortalized human mammary epithelial cells, were plated in 6-well plates at a
density of 80,000 cells per well in 3mL of 76N tert growth media. Cells were grown
overnight at 37°C in a humidified incubation chamber with 5% CO2.
Cell Treatment
After approximately 24 hours of growth, the 76N tert growth medium was removed, cells
were rinsed with PBS, and 3 mL of DMEM-F12 plus antibiotic supplemented with the
appropriate chemical agent was added to each well. Reagents included 9-cis retinoic
acid, estrogen and progesterone (combination treatment), IGF-1, Tamoxifen, TGFβ, and
IGFBP3. Ethanol, DMSO, H2O, and BSA.HCl were used as controls. Each reagent
treatment was performed in triplicate. Reagent concentrations were calculated to imitate
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known physiological levels (Table 4.1). Cells were treated overnight and harvested using
Trizol® at 24 hours and frozen at -80°C pending RNA isolation. The entire experimental
procedure was performed twice to confirm experimental results.
RNA Isolation
Cell lysates suspended in the Trizol® reagent were thawed and 200 µL
chloroform was added. Lysates incubated at room temperature for 3 minutes and were
then centrifuged at 12 x g for 15 minutes. The aqueous layer was transferred to a new
tube and 500 µL of 100% isopropanol was added and samples were then centrifuged.
After centrifugation, 1 mL of 75% ethanol was added and samples were allowed to
precipitate for at least two hours at -20°C. Samples were then removed from the freezer,
centrifuged at 7500 X g for 5 minutes, and liquid was removed from the pellet. RNA
pellet was briefly dried and then resuspended in 50 µL of DNase free water, spectroscopy
was performed to measure RNA concentration and purity, and samples were diluted to
100 ng/µL.
Quantitative PCR
PCR reactions to measure CRBP1 induction in the 76N tert mammary epithelial
cell DNA treated with growth inhibiting and growth promoting agents was conducted
using a Mx4000 Multiplex Quantitative PCR system (Stratagene). CRBP1 primers
utilized were F 51 CGGGTTCGGAACTATATCATGGACTTCTCGA 31 and
R 51 AATTCAAAAATCGGAACTATATCATGGACTTC 31 and GAPDH was used as a
control for the experiment with primers F 51 CCATGGAGAAGGCTGGGG 31 and
R 51 CCAAGTTGTCATGGATGACC 31. 1 µL of RNA was amplified in a 10 µL
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reaction mixture containing 2.4 µL of Mastermix (Brilliant® SYBR® Green QPCR
Mater Mix, Stratagene), 2.4 µL of DNase fee water, 0.6 µL each of 12.5nM primers, and
0.4 µL of RT. Each PCR product was amplified over 40 cycles at an annealing
temperature of 55°C. Included with each PCR were a series of controls.
PCR Analysis
In order to analyze the PCR results, each of the experimental runs was broken into
three separate PCR runs based on their respective control agents due to the limited
sample space for each run. The first PCR panel includes 9-Cis RA, combination estrogen
and progesterone treatment, and IGF-1 with ethanol as their controls (Figure 4.1 & 4.2).
The second panel includes IGFBP3 with ethanol as its control and insulin with water as
its control (Figure 4.3 &4.4). Finally, the third panel includes Tamoxifen with a DMSO
control and TGF-β with BSA.HCl as its control (Figure 4.5 &4.6). GraphPad Prism™
was used for statistical analysis and graphing.
Results
CRBP1 is regulated in response to both growth inhibiting and growth enhancing
agents. Our experiment confirmed that CRBP1 is significantly upregulated in response to
9-cis RA and TGFβ. In experiment 1, the 9-cis retinoic acid treatment had a great deal of
error and was consequently not significant, but in experiment 2 it significantly
upregulated CRBP1 expression as we expected (P value 0.0175). This confirms that as a
downstream member of the retinoic acid pathway that CRBP1 expression is positively
altered in response to retinoic acid. The effect of TGFβ treatment on CRBP1 expression
was very significant (P values 0.001) and was confirmed in both experiments. These
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highly significant results indicate that TGFβ alone is sufficient to upregulate CRBP1
expression.
This experiment also confirmed that CRBP1 is negatively regulated by IGF-1 in
76N tert cells. We had previously observed that IGF-1 could inhibit estrogen and
progesterone upregulation of CRBP-1 and hypothesized that it would decrease CRBP1
expression even in the absence of the hormones. IGF-1 inhibition of CRBP-1 expression
was highly significant (P values 0.0042 & 0.0038 respectively) and resulted in
approximately a 50% reduction in CRBP1 expression.
Based on the results of our initial mouse experiment and other research, we
hypothesized that the combination estrogen and progesterone treatment would
significantly upregulate CRBP1 in the human mammary epithelial cells. The results of
our PCR analysis did not confirm our hypothesis as CRBP1 was not regulated at all in
response to this treatment in either experiment. Error in the experiment was low so we
suspect that this result is due to low levels of the estrogen receptor and/or the
progesterone receptor. In addition to estrogen and progesterone, insulin also did not have
an affect on CRBP1 expression in 76N tert cells.
The results of this experiment were inconclusive for both Tamoxifen and
IGFBP3. The results for Tamoxifen in this study were mixed. In experiment 1, treatment
with Tamoxifen did not positively regulated CRBP1 expression, but in experiment 2 it
did (P value 0.03). These inconclusive results could be the result of treatment error or a
number of other factors such as receptor level. IGFBP3 also had mixed effects on
CRBP1 expression. In experiment 1, IGFBP3 significantly decreased CRBP1 expression
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(P value 0.0090, but this effect was lost in the second experiment. It is important to note
however that both IGFBP3 and its ethanol control had large margins of error in the
second experiment. The effects of Tamoxifen and IGFBP3 on CRBP1 expression cannot
be fully explained by this study and need to be further investigated for more definitive
answers.
Discussion
It is clear from the results of this experiment that CRBP1 is regulated by both
growth inhibiting and growth enhancing agents. CRBP1 has been implicated in having a
role in regulating cell proliferation and has even been suggested to be a tumor
suppression gene (Farias et al. 2005). A better understanding of how CRBP1 is regulated
provides important clues about the specific mechanisms of how it regulates cell growth
and also provides insight into what loss of CRBP1 during cancer progression might
cause. This study revealed several important findings that contribute to our knowledge of
CRBP1 regulation and also highlights the challenge of replicating physiological
conditions in an in vitro cell culture system.
One of the major challenges with conducting a cell treatment experiment is
determining how long it takes for the reagent to take affect. Prior to conducting the
experiments that are being explored in this chapter, we conducted an initial 24-hour
treatment and a 48-hour treatment study with a smaller selection of chemical treatments
to determine the ideal treatment time. The PCR results for CRBP1 at both the 24hour
and 48 hour time points showed that there was little to no difference between them in
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terms of statistical significance and observed trends. Therefore, we chose to utilize the
24-hour treatment window for the larger experiment.
CRBP1 is an integral part of the retinoic acid pathway and is has been previously
shown to be upregulated by retinoic acid treatment (Zaitseva et al. 2008). When
designing the experiment, we fully expected that 9-Cis RA should significantly
upregulate CRBP1 since this gene is a transporter of retinoic acid in the cell. We were
initially surprised to find that CRBP1 expression was only significantly increased in one
of the experiments (Figure 4.2). Upon closer examination, it is likely that error played a
large role in experiment 1 resulting in treatment with RA not being significant (Figure
4.1). Based on these observations, we conclude that CRBP1 is positively regulated by 9Cis RA in the mammary epithelial cell. Further experiments could be conducted to test
the effect of other forms of retinoic acid on CRBP1 expression, such as all-trans RA, and
strengthen our finding.
Based on the findings in our mouse study that demonstrated that CRBP-1 is
persistently upregulated in response to pregnancy in vivo in the mouse mammary gland,
we hypothesized that CRBP-1 would be significantly upregulated in response to the
combination treatment of estrogen and progesterone which mimics physiological levels
of the hormones that are found during pregnancy in human mammary epithelial cells.
After completing the statistical analysis using the PCR data, we found that estrogen and
progesterone did not regulate CRBP1 in the 76N tert cells in either experiment (Figures
4.1 &4.2). In fact, there was not even a trend toward regulating CRBP1. In an effort to
explain this unexpected result, it is important to consider the differing environments of
the cultured cell and the intact mammary gland. In vivo, the mice have their own estrous
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cycle controlling internal hormone levels in the mammary gland. As the cultured cells
are do not have a regular hormone cycle that is replicated in the cell in vitro. Also, it is
possible that the estrogen contained in the 76N tert growth media during the first 24
hours of culture could be confounding our results. Analysis of mouse tissue treated with
with estrogen and progesterone (Personal communication from Lesley Mathews) or
various estrogen alpha and beta agonists (Personal communication from Eric Roman
Perez) support that CRBP1 is positively regulated by estrogen, so this is likely an artifact
of tissue culture or a requirement for other cell types present in the mammary gland to
provide paracrine signals in response to estrogen.
The major finding from this study is that CRBP1 is negatively regulated by
growth enhancing agent IGF-1 even in the absence of hormone induction. IGF-1
treatment reduced CRBP1 gene expression significantly in both of the experimental runs
with p values of 0.0042 and 0.0038 respectively. IGF-1 has been previously shown to
block CRBP1 upregulated expression, but its effects on normal expression levels of
CRBP1 were not known. Additionally, it appears that IGF-1 is specifically required to
mediate insulin-related effects on CRBP1 as its expression was not impacted by insulin
treatment alone.
In conclusion, CRBP1 is regulated by growth enhancers and inhibitors in 76N tert
human mammary epithelial cells. Future experiments should focus on reexamining the
effects of Tamoxifen and IGFBP3 on CRBP1 expression and should also seek out
additional known growth effectors to test and further strengthen what is known about
CRBP1 regulation.
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Table 4.1 Summary of treatment concentrations used in 76N tert experiments
Summary of Treatment Concentrations Used in 76N tert Experiments
Stock
Amount used per mL of
Treatment
Concentration
media
9-Cis Retinoic
1µL/mL
Acid
1mM
1µg/mL
1µL/mL
Estrogen
1µL/mL
Progesterone
1mg/mL
1µL/mL
Tamoxifen
1mM
2.5µL/mL
TGF beta
10 ng/mL
100µg/mL
1µL/mL
IGF-1
2.5µL/mL
Insulin
10mg/mL
250µg/mL
1µL/mL
IGFBP3
1µL/mL
EtOH
100%
1µL/mL
DMSO
100%
2.5µL/mL
BSA.HCl
4mM
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Figure 4.1 PCR analysis for CRBP1 expression in 76N tert cells treated in vitro with
EtOH, 9-cis RA, combined estrogen and progesterone, and IGF-1
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Figure 4.2 PCR analysis for CRBP1 expression in 76N tert cells treated in vitro with
DMSO, Tamoxifen, BSA.HCl, and TGF beta
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Figure 4.3 PCR analysis for CRBP1 expression in 76N tert cells treated in vitro with
EtOH, IGFBP3, water, and insulin
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CHAPTER 5
EXPLORING THE EFFECTS OF BREAST CANCER RISK FACTORS ON GENE
INACTIVATION THROUGH PROMOTER HYPERMETHYLATION

Introduction
Breast cancer arises as the result of a characterized multi-step process that
includes the loss of cell cycle regulation and alterations to gene expression. Normally,
the body maintains a careful balance of oncogenes and tumor suppressive gene
expression, however, in cancer oncogene expression is frequently upregulated while
tumor suppressive gene expression is often lost. In recent years, research into the
epigenetics of cancer has become a major field of study. One important epigenetic
change observed in breast cancer is CpG dinucleotide methylation in the promoter region
of specific genes. This aberrant methylation alters the expression of the effected gene
and aids cancer growth (Dworkin et al. 2009). We propose that examining changes in
promoter methylation in genes commonly altered in breast cancer using benign tissue
may provide important insight into the relationship between breast cancer risk factors and
promoter methylation.
Epidemiological studies indicate a number of risk factors that may contribute to
risk of developing breast cancer for women including age, parity status, and family
history (American Cancer Society 2009). Age is an important risk factor for cancer.
Specifically, as women age their cells accumulate DNA damage, increasing their
likelihood of developing breast cancer (Euhus et al. 2008). Another important risk factor
for breast cancer is parity status. It has been well documented that women who have fullterm pregnancy before the age of 24 have a lifetime decreased risk of developing the
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disease (Russo et al. 2005). This observation is often attributed to changes in gene
expression and breast architecture that occur during pregnancy, lactation, and involution.
Family history is also an important risk factor for breast cancer. Women with a first
degree relative (parent, sibling, or offspring) who have had breast cancer have nearly
double the risk of developing the disease and having a secondary relative (aunt/uncle,
grandparent, niece/nephew, half sibling) with the disease also increases risk (American
Cancer Society 2009). Each of these risk factors can impact a woman’s likelihood of
developing the disease. We hypothesize that these risk factors may correlate to changes
in promoter methylation in three genes whose expression is often altered in the early
stages breast cancer development, CRBP1, SFRP1, and RASSF1. For this study, we will
compare changes in CpG promoter methylation across these three genes to these risk
factors in an effort to determine if there is a relationship between them. We will also
examine the individual CpG sites for each gene to determine if any sites are particularly
susceptible to methylation.
Epigenetic promoter methylation is a common event early in breast cancer
progression. Although there are many genes that are frequently methylated with breast
cancer, three such genes, CRBP1, SFRP1, RASSF1, are the subjects of this study.
Cellular retinol binding protein is an important gene in the retinoic acid pathway and
research has suggested that it may be a tumor suppression gene. CRBP1
hypermethylation has been shown to be the primary mechanism of CRBP1 silencing in
human breast cancer and this phenomenon is evolutionarily conserved between humans
and mice (Esteller et al. 2002, Arapshian et al. 2004).
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SFRP1 belongs to a family of genes known to antagonize the Wnt pathway. Wnt
regulates cell proliferation and differentiation and normally binds Frizzled receptor
(FZD). SFRP-1 inhibits Wnt signaling by competing with Frizzled for the Wnt binding
domain. SFRP1 is located in a chromosomal region that is often deleted in breast cancer
and has also been shown to be frequently methylated in patients with the disease (Suzuki
et al. 2008). Therefore, loss of SFRP1 gene expression through promoter methylation
can result in an overexpression of Wnt leading to unregulated cell proliferation,
contributing to the progression of breast cancer.
Finally, RASSF1 is a gene that plays an important role in DNA damage repair and
apoptosis. Encoding RAS effector proteins, RASSF1 interacts with DNA repair protein
XPA and is required for death receptor-dependent apoptosis. Additionally, RASSF1
inhibits the accumulation of Cyclin D1 in the cell resulting in cell cycle arrest and the
inhibition of cell proliferation. Studies have suggested that RASSF1 is an important
tumor suppression gene based on its role in DNA damage repair and its frequent
hypermethylation in cancer (Hesson et al. 2007).
In order to study to the effects of age, parity, and family history on promoter
methylation of our chosen genes, it was necessary to find a source of cells that varied
with respect to these variables. We chose to utilize human mammary epithelial cells that
were harvested from donated tissue from women undergoing reduction mammoplasty
surgery at Baystate Hospital in Springfield, MA. Due to an ongoing study between the
Smith Schneider lab and the Jerry lab and the surgical and oncology departments at the
hospital, women undergoing breast reduction surgeries at the hospital were propositioned
to donate their tissue to cancer research. Mammary epithelial cells were then harvested
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and cultured from these tissues and were used in this study. In addition to donating their
tissue, women participating in the study were asked various questions about themselves
including their age, number of full-term pregnancies, and family history of breast cancer.
This epidemiological data was utilized to help us understand the methylation analysis we
conducted.
Pyrosequencing has emerged as the preferred method for analyzing DNA
methylation (Reed at al. 2009). CpG sites are located in the promoter regions of genes
making them a prime target for methylation. DNA methylation results in a methyl group
being attached to the cytosine next to the guanine in the CpG island. The first step in
methylation analysis is to decipher between cytosines that have been methylated and
those that have not. Bisulfite modification of sample DNA converts all unmethylated
cytosines to uracil, allowing the methylated cytosines to be easily identified. After
bisulfite modification, PCR analysis is used to amplify the DNA for pyrosequencing.
Finally, pyrosequencing analysis of each individual CpG sites for your chosen gene is
conducted and provides a percent measure of methylation for each sample. The resulting
methylation data can then be analyzed to look for trends and statistically significant
findings. For our study, we chose to outsource the bisulfite modification, PCR
amplification, and pyrosequencing to EpigenDX, a company specializing in this type of
analysis based on Worcester, MA. For our statistical analysis and graphing, we used
STATA™ Data analysis and statistical software.
After analyzing the patient samples in our initial pool of 22 women, we concluded
that our small number of samples was not sufficient to reach statistical significance. To
overcome this limitation, we chose to combine our methylation data with another sample
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set of 102 women provided by Kathleen Arcaro, a collaborator in this study. Unlike the
human mammary epithelial cells that were cultured from reduction mammoplasty tissue
for the initial analysis, the epithelial cells isolated for the methylation study in the Arcaro
lab were from human breast milk samples. The Arcaro lab completed their own bisulfite
modification and PCR amplification, but also utilized EpigenDX for pyrosequencing
their samples. STATA™ was again used for the combined data analysis.
In summary, we propose that changes in promoter methylation of three genes,
CRBP1, SFRP1, and RASSF1, may correlate to risk factors such as age, parity status, and
family history. Also, we plan to analyze each individual CpG site for our three genes to
see if patterns of methylation emerge for individual sites. Finally, we will combine our
methylation data with methylation data collected from epithelial cells isolated from breast
milk samples to see if there are correlations between the two sample sets.
Materials and Methods
Acquisition of Donor Samples
Female patients undergoing reduction mammoplasty surgery at Baystate Medical
Center in Springfield, Massachusetts were asked prior to their procedure to donate a
portion of their removed breast tissue by their treating physician or physician assistant.
After surgery, consenting patient tissue was collected within one hour of surgery and
reviewed by a pathologist before being released to researchers at the Pioneer Valley Life
Sciences Institute. Each patient was assigned a random number to protect their identity.
Within 30 days of the procedure, patients were administered a questionnaire by an
outside research personnel. The use of human subjects, which included informed
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consent, was approved by the University of Massachusetts, IRB Human Research
Protection Office (HRPO) and the Baystate Medical Center IRB office. A summary of
the epidemiological data for the 22 patients included in this study is provided in Table
5.1.
Mammary Tissue Processing
Tissue was acquired by research personnel from the Pathology department at
Baystate Medical Center and brought to the laboratory at the Pioneer Valley Life
Sciences Institute in Springfield, Massachusetts. Tissue was finely minced and digested
overnight in mammary digestion media. Any undigested tissue was removed and the
digestion solution was centrifuged at 80 x g for 10 minutes to collect a mammary
epithelial cell pellet. The pellet was then washed in 10 mL of HF epithelial wash and
centrifuged. The pellet was then incubated with 2 mL of trypsin/EDTA for 5 minutes at
room temperature and the HF wash and centrifugation were repeated. The pellet was
then treated with 2 mL dispase and 10 µL DNase I for 5 minutes at room temperature and
then HF wash and centrifugation was repeated. Cells were then passed through 100 µm
and 40 µm cell strainers and centrifuged for 5 minutes at 100 x g. Cell pellet was then
resuspended in 1 mL of mammosphere media, counted, and plated at a density of 20,000
cells per 10 cm ultralow attachment plate. Plates were labeled with patient #, date of
harvest, and date of culture.
Cell Culture
Human mammary epithelial cells (HMECs) were cultured in MEGM
supplemented with bovine pituitary extract for 12-14 days in a 37°C humidified incubator
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with 5% CO2. Plates were examined daily, with the exception of most weekend days, for
the growth of fibroblast cells that would contaminate the epithelial cell population. Upon
examination, if fibroblast count reached approximately 30% of the total cell population,
then the plate was discarded. Cells were grown to approximately 70% confluency prior
to harvesting, but growth rates varied widely between patients and some patient cell
cultures never reached this percentage of confluency and were instead harvested on day
14.
DNA Isolation
Human mammary epithelial cells were harvested either once they reached
approximately 70% confluency or when day 14 of culture was reached, which ever came
first. Cells were detached from their plates using trypsin, growth media was added to
reduce stress on cells during harvesting, cells were centrifuged to form a pellet, trypsin
and media was removed, and the pellet was resuspended in 200 µL of 1XPBS. All
patient human mammary epithelial cell DNA was isolated using a Qiagen DNeasy Blood
and Tissue Kit® and kit procedures were followed for isolation. After DNA was
isolated, DNA quality and yield was measured via spectroscopy. Final DNA yield
ranged widely from 30ng/µL to 524ng/µL. DNA samples were labeled with the patient’s
randomly assigned number and DNA concentration and were then overnighted to
EpigenDX for analysis.
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Bisulfite modification & Pyrosequencing
Bisulfite modification, PCR amplification, and pyrosequencing analysis were all
conducted by EpigenDX in Worcester, MA. Methylation data was analyzed using
regression analysis and graphed using STATA™ Data analysis and statistical software.
Results
Mean Methylation by CpG Site
Due to the small sample size, there are no statistically significant findings from
the patient tissue samples, but there are interesting observations to be made. It has been
demonstrated that certain CpG sites are more susceptible to methylation than others
(Ref). Based on this, our first analysis was to examine the mean methylation scores for
individual CpG sites for each gene. For CRBP1, although there are 19 total CpG sites,
the pyrosequencing was unable to accurately collect methylation data past site 8, so we
only examined the first 8 sites in our analysis. Examination of the individual CpG site
percent methylation ranges revealed that overall CRBP1 methylation was low (below
5%) in our patients (Figure 5.1). Only three CpG sites had a patient whose score was
over 5%, sites 3, 6, and 8. When you compare the patient profiles in terms of risk factors
for the sample over 5% there is no pattern to them. What this suggests is that these three
sites have variance with respect to CRBP1 methylation and could warrant further
investigation, although the results of this study were inconclusive due to our small sample
size.
SFRP1 had more methylation overall when compared with CRBP1. Every CpG
site had at least one patient over 5% methylation and several sites had 3 or more patients
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over 5% (sites 2 , 5 , 6, 7) (Figure 5.2). Similar to CRBP1, when you compare the
individual patients between the CpG sites there is no pattern that emerges. Women that
were highly methylated in one site were not in others and there were no risk factor
groupings. Like SFRP1, RASSF1 had an overall higher methylation than CRBP1.
Again, there are several sites of interest (sites 3, 5, 6 ,7, 8), but patient comparisons do
not reveal interesting trends (Figure 5.3). Our low sample numbers limited the statistical
analysis of our data and to fully explore if the sites with methylation above 5% for three
or more patients are important the experiment would need to be repeated with additional
patients.
Risk Factors and Mean Methylation Analysis
After examining mean methylation by CpG site for each gene, we turned to
examine how risk factors may impact mean methylation for each gene. First, we
investigated if current age had an effect on mean methylation. As is shown in Figure 5.4,
there is no significant trend. We had hypothesized that as women age they would
accumulate more methylation, but our data does not support that proposition. When you
examine the methylation by gene, CRBP1 has low methylation overall and increasing age
has no effect on mean methylation (Figure 5.5). SFRP1 also has low methylation overall,
but the only two patients having methylation greater than 5% are over the age of 45
(Figure 5.6). Although this is an interesting observation, our low patient numbers do not
make this finding significant, but do suggest that further investigation might be
warranted. Finally, examination of RASSF1 mean methylation versus current age does
not reveal any interesting trends (Figure 5.7). Increased patient numbers, and perhaps an
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increase in patient over 50 years of age, should be considered if this analysis is to be
repeated more accurately.
After examining the affect of age on methylation, we turned to the role of
pregnancy generally and early pregnancy on mean methylation for each gene. We
hypothesized that women who have had an early full-term pregnancy should have lower
mean methylation scores in comparison with women who have not. It is important to
note that the number of patients who had ever had a full-term pregnancy was only 8 out
of the 22 total patients whom we have data on. First, we analyzed how the number of
live births a woman has undergone impacted mean methylation scores for all three genes
(Figure 5.8). Overall, methylation scores were below 5% and the only similarities
between the women above 5% were that two of them had two pregnancies each and also
have high methylation for SFRP1.
Pregnancy alone is not enough to garner protection against breast cancer. The age
of the women during the time of her first pregnancy is important because studies have
documented that women who undergo a full-term pregnancy before the age of 24 have a
lifetime decreased risk of developing the (Russo et al. 2005). In order to account for this,
we then analyzed the age of the women at the time of their first pregnancy versus the
mean methylation score (Figure 5.9). Again, overall methylation scores were low, but
the two patients that had high methylation scores in the first analysis were shown to be
age 26 and 32 respectively at the time of their first pregnancy. Although these ages are
not in the protective range, they are also not above age 35 and consequently at a higher
risk. It is difficult given the limited sample size to draw conclusions about this
observation regarding SFRP1 analysis, but it was important to point out.
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Finally, family history of breast cancer is another important risk factor we chose
to examine in this study. When comparing women who have no family history with
women who have either a first or second degree relative with the disease in terms of their
mean percent methylation scores, no interesting pattern emerges (Figure 5.10).
Combined Epithelial Cell Data Analysis
In an effort to supplement the limited mammoplasty tissue samples in our study,
we combined our methylation data set of 22 patients with methylation data from 102
additional samples that were also pyrosequenced for the same three genes by EpigenDX.
Our collaborator, Kathleen Arcaro, conducted pyrosequencing analysis on epithelial cells
collected and purified from breast milk samples from lactating women. Similar to our
study, we received current age and parity status information on these additional samples.
After combining the two data sets, we wanted to investigate whether the source of
the mammary epithelial cells had any effect on mean methylation scores. First a
regression analysis was completed for RASSF1 for cell source while controlling for
current age with 124 total samples. What this analysis showed was that cells derived
from the milk samples had a significantly higher mean methylation score than cells
derived from the reduction mammoplasty tissue (P value 0.033). Current age did not
exhibit a significant trend. As is shown in Figure (5.11), graphing the mean methylation
scores for RASSF1 over the cell source reveals a number of very high methylation scores
that could have been confounding our results. In order to demonstrate that the higher
mean methylation scores for cells derived from the milk samples were accurate, the
regression was performed again removing all methylation scores above 10.31 (or 8
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samples). Removing the samples above 10.31% methylation only strengthened our
finding that epithelial cells derived from milk samples have a higher mean methylation
score than cells derived from the reduction mammoplasty tissue (P value 0.029). Finally,
although current age is an important variable to control for in the regression analysis, we
hypothesized that parity may also play an important role in mean methylation scores in
that based on the role of parity-induced protection, parous women might have lower
mean methylation scores that nulliparous women. Given this possible confounding of
our significant findings, the regression analysis was repeated taking parity into account
(119 samples). After controlling for both current age and parity status, epithelial cells
derived from milk were still shown to have an even more significantly increased (P value
0.007) mean methylation scores when compared to cells derived from reduction tissue.
Additionally, after controlling for parity status, there is an observed trend that current age
may be impacting mean methylation (P value 0.075). Based on our results, parity status
appears to play no significant role in mean methylation score.
After observing that epithelial cells derived from breast milk samples had higher
mean methylation scores than those from reduction mammoplasty tissue, the analysis was
repeated for CRBP1. First a regression analysis was completed for cell source while
controlling for current age with 116 samples. Similar to RASSF1, cells derived from the
milk samples had a significantly higher mean methylation score (P value 0.00). Current
age did not exhibit a significant trend. As is shown in Figure 5.12, graphing the mean
methylation scores for CRBP1 over the cell source reveals a number of very high
methylation scores that could have been confounding our results. In order to demonstrate
that the higher mean methylation scores for cells derived from the milk samples were
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accurate, the regression was performed again removing all methylation scores above
10.15 (or 5 samples). Epithelial cells derived from milk samples once again had a
significant increase in mean methylation scores (P value 0.00) versus cells derived from
the reduction mammoplasty tissue. Finally, although current age is an important variable
to control for in the regression analysis, we hypothesized that parity may also play an
important role in mean methylation scores in that parous women should have lower mean
methylation scores that nulliparous women. Given this possible confounding of our
significant findings, the regression analysis was repeated taking parity into account (113
samples). After controlling for both current age and parity status, epithelial cells derived
from milk were still shown to have significantly increased (P value 0.00) mean
methylation scores when compared to cells derived from reduction tissue. For CRBP1,
there was no significant trend for current age or parity having an effect of mean
methylation scores.
After observing that epithelial cells derived from breast milk samples had higher
mean methylation scores than those from reduction mammoplasty tissue for both
RASSF1 and CRBP1, the analysis was repeated for SFRP1. Initially, a regression
analysis was completed for cell source while controlling for current age with 122
samples. Similar to RASSF1 and CRBP1, cells derived from the milk samples had a
higher mean methylation score that was significant (P value 0.048). Current age did not
exhibit a significant trend. As is shown in Figure 5.13, graphing the mean methylation
scores for SFRP1 over the cell source reveals a number of high methylation scores that
could have be outliers confounding our results. In order to demonstrate that the higher
mean methylation scores for cells derived from the milk samples were accurate, the
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regression was performed again removing all methylation scores above 13.76 (or 7
samples). Epithelial cells derived from milk samples once again had a significant
increase in mean methylation scores (P value 0.011) versus cells derived from the
reduction mammoplasty tissue. As was explained earlier, although current age is an
important variable to control for in the regression analysis, parity is another risk factor for
breast cancer that could account for the higher mean methylation scores we observed.
Given this possible confounding of our significant findings, the regression analysis was
repeated taking parity into account (118 samples). After controlling for both current age
and parity status, the trend of epithelial cells derived from milk having a significantly
increased mean methylation scores when compared to cells derived from reduction tissue
was lost (P value 4.60). For SFRP1, there was no significant trend for current age or
parity having an effect of mean methylation scores. In conclusion, parity status, although
it does not significantly impact mean methylation scores in it of itself, controlling for
parity does result in a loss of difference in mean methylation scores we observed between
epithelial cells derived from milk and those derived from reduction mammoplasty tissue.
Discussion
In this experiment, we proposed that the amount of CpG promoter methylation of
RASSF1, CRBP1, and SFRP1 would vary with respect to specific CpG sites and that
promoter methylation is related to breast cancer risk factors such as parity status, age, and
family history of the disease. Although our data did indicate differing levels of mean
percent methylation for individual CpG sites for each of the genes we examined, our
sample numbers were too low to make strong conclusions about these observations. In
terms of the risk factors we examined, although there were some interesting findings,
53

overall the methylation scores for the patients we analyzed were low (below 5%) and no
significant trends could be indentified relating specific risk factors to increased
methylation. Although significance was not reached in this experiment, this study did
introduce a new technique for methylation analysis to the lab and paves the way for
future patient studies that can build upon our currently limited data. Also, we were able
to observe several challenges inherent to relying upon patient data and culturing HMEC
cells that will be helpful to other researchers in our lab.
There were several major challenges we experienced when completing this
experiment. The study relies upon women undergoing breast reduction surgeries at
Baystate Hospital in Springfield, MA consenting to donate their tissue and being willing
to complete a survey to collect personal information afterwards. As is evident upon
examining Table 5.1, there were many women who initially consented to the study, so
their tissue was collected and their cells were put into culture, but later failed to complete
the survey. This resulted in several patients being included in the study with only agerelated information, the one piece of data we have on all patients at the time of tissue
harvesting. Although this did not inhibit our analysis of age in the study, it did drastically
reduce the number of patients in our analysis of parity status and family history in
promoter methylation. Given our relatively small sample number, these reductions in
usable patient data negatively impacted our statistical analysis. To account for this
problem in future experiments, the number of patients needed should be overestimated to
account for failure of some patients to complete the needed personal information survey.
Another challenge we experienced in conducting this experiment was working
with the human mammary epithelial cells (HMECs) isolated from the reduction
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mammoplasty tissue. HMEC cells were difficult to culture. Several of our initial patients
we had hoped to include in the study had to be excluded because their cells died in
culture or their mammary epithelial cells became overrun with fibroblasts while in
culture. The tissue digestion process used to isolate the mammary epithelial cells did not
have a mechanism for enriching for this particular cell population, resulting in a mix of
epithelial cells and fibroblasts being plated. In addition to being difficult to maintain in
culture, variance in growth rates, and the mixed cell population, DNA yields and purity
varied widely and at times were not sufficient for the necessary bisulfite modification and
pyrosequencing requirements for the study. Initially, we had intended to complete the
bisulfite modification to covert all unmethylated cytosines to uracil, a necessary step
prior to pyrosequencing, in the lab. Although we successfully bisulfite modified several
patient samples, the process resulted in the loss of overall DNA yield. Given the
relatively low amount of DNA isolated from the cells and the fact that for many patients
we only had one plate that was available to harvest and could not pool patient DNA from
multiple plates this posed a major problem and caused us to outsource our bisulfite
modifications and PCR amplifications to EpigenDX, who was able to complete the
modifications with smaller amounts of DNA.
One of the most interesting observations to come out of this study is that human
mammary epithelial cells derived from reduction mammoplasty tissue and those derived
from breast milk were significantly different with respect to mean percent methylation.
There are three major differences between the mammoplasty epithelial cells and the
breast milk epithelial cells that could explain this finding. The first difference is the
cellular environment at the time of collection and method of cell isolation. The
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mammoplasty epithelial cells were isolated and cultured from intact tissue for up to two
weeks and there was no enrichment for the epithelial cell population. The breast milk
cells were exfoliated by the breast during lactation and were collected and purified
directly from the milk samples and were never grown in culture. Also, they were able to
enrich for the epithelial cells through epithelial-specific MACS HEA-125 microbeads
(Miltenyi Biotec, Germany). Another difference to consider between the two cell
populations is that all of the women in the milk sample have had at least one full-term
pregnancy and were lactating at the time the milk samples were collected in contrast with
the more varied population in reduction mammoplasty pool. Finally, the Arcaro lab
completed their own bisulfite modification and PCR amplification of the DNA prior to
sending the samples to EpigenDX while our samples were sent as unmodified DNA to
EpigenDX and they completed the bisulfite modification, PCR amplification, and
pyrosequencing. It is possible that any of these differences between the two sample sets
could explain our observation that milk cells are significantly different than
mammoplasty cells with respect to mean methylation.
In conclusion, although there were limited statistically significant findings in this
study, a new technique was successfully introduced to our lab and interesting
observations were made about CpG promoter methylation of CRBP1, SFRP1, and
RASSF1 that can be built upon by other researchers. Additional investigation into the
specific CpG sites targeted by hypermethylation in each of these three genes is needed
and the relationship between breast cancer risk factors and methylation also requires
further examination. Our hypotheses in this study were not confirmed, but instead,
remain inconclusive.
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Table 5.1 Summary of patient epidemiological data

Summary of Patient Data
#
Current Age
GRAVA PARA
Age at 1st Birth
Family History
1
54
2
17
0
0
0
No
3
29
0
0
0
No
4
21
0
0
0
Yes (2°)
5
38
6
27
2
0
0
Yes (2°)
7
16
0
0
0
Yes (2°)
8
34
0
0
0
No
9
23
1
1
17
No
10
52
3
3
18
No
11
55
2
2
32
Yes (1°)
12
44
4
3
30
Yes (2°)
13
56
14
35
15
56
16
18
0
0
0
No
17
34
1
1
30
Yes (1°)
18
50
0
0
0
No
19
39
1
1
27
No
20
59
4
3
19
No
21
25
1
0
0
No
22
49
3
2
26
No
Blank cells indicate that data is missing
1°= First degree relative with breast cancer (parent, sibling, offspring)
2°= Second degree relative with breast cancer (grandparent, aunt, niece, halfsibling)
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Figure 5.1 CpG site-specific analysis for CRBP1 promoter methylation

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.2 CpG site-specific analysis for SFRP1 promoter methylation

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.3 CpG site-specific analysis for RASSF1 promoter methylation

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.4 Examination of how current age may affect CpG mean percent methylation of
CRBP1, SFRP1, and RASSF1

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.5 Examination of how current age may affect CpG mean percent methylation of
CRBP1

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.6 Examination of how current age may affect CpG mean percent methylation of
SFRP1

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.7 Examination of how current age may affect CpG mean percent methylation of
RASSF1

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.8 Examination of how number of live births may affect CpG mean percent
methylation of CRBP1, SFRP1, and RASSF1

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.9 Examination of how age at first pregnancy may affect CpG mean percent
methylation of CRBP1, SFRP1, and RASSF1

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.10 Examination of how family history may affect CpG mean percent
methylation of CRBP1, SFRP1, and RASSF1

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.11 Examination of how source of mammary epithelial cells from either
reduction mammoplasty tissue or breast milk affects RASSF1 mean methylation

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.12 Examination of how source of mammary epithelial cells from either
reduction mammoplasty tissue or breast milk affects CRBP1 mean methylation

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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Figure 5.13 Examination of how source of mammary epithelial cells from either
reduction mammoplasty tissue or breast milk affects SFRP1 mean methylation

Red bar indicates 5% methylation. Samples below the line are considered to have low
levels of methylation.
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